LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
Astria Therapeutics Analyst Ratings
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $25
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
TD Cowen Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $35
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating